- Home
- SBRA vs IOVA Comparison
SBRA vs IOVA Comparison
Compare SBRA & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- IOVA
- Stock Information
- Founded
- SBRA 2010
- IOVA 2007
- Country
- SBRA United States
- IOVA United States
- Employees
- SBRA N/A
- IOVA N/A
- Industry
- SBRA Real Estate Investment Trusts
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBRA Real Estate
- IOVA Health Care
- Exchange
- SBRA Nasdaq
- IOVA Nasdaq
- Market Cap
- SBRA N/A
- IOVA 771.4M
- IPO Year
- SBRA N/A
- IOVA N/A
- Fundamental
- Price
- SBRA $18.47
- IOVA $1.88
- Analyst Decision
- SBRA Buy
- IOVA Buy
- Analyst Count
- SBRA 7
- IOVA 10
- Target Price
- SBRA $19.71
- IOVA $12.22
- AVG Volume (30 Days)
- SBRA 2.5M
- IOVA 10.4M
- Earning Date
- SBRA 08-06-2025
- IOVA 08-07-2025
- Dividend Yield
- SBRA 6.50%
- IOVA N/A
- EPS Growth
- SBRA 185.79
- IOVA N/A
- EPS
- SBRA 0.60
- IOVA N/A
- Revenue
- SBRA $720,247,000.00
- IOVA $212,679,000.00
- Revenue This Year
- SBRA $5.91
- IOVA $86.62
- Revenue Next Year
- SBRA $5.30
- IOVA $69.95
- P/E Ratio
- SBRA $30.82
- IOVA N/A
- Revenue Growth
- SBRA 10.76
- IOVA 11070.12
- 52 Week Low
- SBRA $15.49
- IOVA $1.64
- 52 Week High
- SBRA $20.03
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- SBRA 54.92
- IOVA 47.47
- Support Level
- SBRA $18.27
- IOVA $1.68
- Resistance Level
- SBRA $18.56
- IOVA $2.02
- Average True Range (ATR)
- SBRA 0.32
- IOVA 0.11
- MACD
- SBRA -0.02
- IOVA 0.03
- Stochastic Oscillator
- SBRA 55.43
- IOVA 61.42
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.